Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)

Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion.

There's a bright future ahead for this company.

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).

Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water.

The biotech could be worth a lot more in 10 years.

One player's minor pain is another's moderate gain.